GLP-1 AGONISTS IN PSYCHIATRY — A NEW THERAPEUTIC DIRECTION FOR DEPRESSION, ADDICTIONS, AND EATING DISORDERS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6114Keywords:
GLP-1 Receptor Agonists, Substance Use Disorders, Eating Disorders, Neuroinflammation, PsychiatryAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed for the treatment of type 2 diabetes mellitus and obesity, are increasingly being investigated for their potential relevance to psychiatric disorders. Accumulating preclinical and clinical evidence indicates that GLP-1 signaling extends beyond metabolic regulation and may influence central mechanisms implicated in mood regulation, motivational processing, compulsive reward-seeking, and interoceptive control. This review synthesizes current mechanistic, preclinical, clinical, and registry-based evidence concerning the possible role of GLP-1 RAs in psychiatry, with particular emphasis on major depressive disorder, substance use disorders, and eating disorders. The biological rationale for their psychiatric relevance is supported by evidence of GLP-1-mediated signaling through circumventricular organs, vagal–brainstem pathways, and selected central nervous system regions, including hypothalamic, hippocampal, and mesolimbic reward-related circuits. Proposed mechanisms include modulation of reward salience, attenuation of neuroinflammatory signaling, improvement of metabolic-inflammatory burden, and enhancement of neuroplastic processes.
The clinical evidence remains heterogeneous and indication-specific. In depression, the most consistent findings relate to cognitive and motivational domains, particularly in patients with major depressive disorder and coexisting overweight or obesity, whereas broader evidence from metabolic trials suggests modest reductions in depressive symptoms without establishing disorder-specific antidepressant efficacy. In substance use disorders, alcohol use disorder currently represents the most advanced area of investigation, with semaglutide demonstrating favorable outcomes in a phase 2 trial, while exenatide showed no overall reduction in heavy drinking but reduced alcohol cue reactivity and suggested potential benefit in obese participants. Evidence for nicotine use disorder is mixed, and data concerning opioid and stimulant use disorders remain preliminary. In eating disorders, binge-eating phenotypes appear to be the most plausible therapeutic target, whereas evidence for bulimia nervosa is limited and anorexia-spectrum disorders raise important safety concerns due to appetite suppression and weight loss. Overall, the safety profile of GLP-1 RAs in psychiatric populations appears broadly consistent with their established metabolic use, with gastrointestinal adverse effects predominating; however, psychiatric monitoring remains advisable because observational safety data are not fully concordant. Current evidence supports further diagnosis-specific randomized controlled trials but does not yet justify routine psychiatric prescribing outside carefully selected clinical contexts or research settings.
References
Allison, K. C., Chao, A. M., Bruzas, M. B., McCuen-Wurst, C., Jones, E., McAllister, C., Gruber, K., Berkowitz, R. I., Wadden, T. A., & Tronieri, J. S. (2023). A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obesity Science & Practice, 9(2), 127–136. https://doi.org/10.1002/osp4.619
Angarita, G. A., Matuskey, D., Pittman, B., Costeines, J. L., Potenza, M. N., Jastreboff, A. M., Schmidt, H. D., & Malison, R. T. (2021). Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug and Alcohol Dependence, 221, 108614. https://doi.org/10.1016/j.drugalcdep.2021.108614
Aoun, L., Almardini, S., Saliba, F., Haddadin, F., Mourad, O., Jdaidani, J., Morcos, Z., Al Saidi, I., Bou Sanayeh, E., Saliba, S., Almardini, M., & Zaidan, J. (2024). GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review. Journal of Clinical & Translational Endocrinology, 35, 100333. https://doi.org/10.1016/j.jcte.2024.100333
Badulescu, S., Gill, H., Shah, H., Brudner, R., Phan, L., Di Vincenzo, J. D., Tabassum, A., Armanyous, M., Llach, C.-D., Rosenblat, J. D., McIntyre, R. S., & Mansur, R. B. (2026). Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial. Med, 7(1), 100916. https://doi.org/10.1016/j.medj.2025.100916
Bartel, S., McElroy, S. L., Levangie, D., & Keshen, A. (2024). Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. The International Journal of Eating Disorders, 57(2), 286–293. https://doi.org/10.1002/eat.24109
Beutler, L. R. (2026). GLP-1 physiology and pharmacology along the gut-brain axis. The Journal of Clinical Investigation, 136(2), e194744. https://doi.org/10.1172/JCI194744
Cai, M., Choi, T., Xie, Y., & Al-Aly, Z. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among us veterans with type 2 diabetes: Cohort study. BMJ, 392, e086886. https://doi.org/10.1136/bmj-2025-086886
Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024). The antidepressant effects of GLP-1 receptor agonists: A systematic review and meta-analysis. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 32(1), 117–127. https://doi.org/10.1016/j.jagp.2023.08.010
Da Porto, A., Casarsa, V., Colussi, G., Catena, C., Cavarape, A., & Sechi, L. (2020). Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study. Diabetes & Metabolic Syndrome, 14(4), 289–292. https://doi.org/10.1016/j.dsx.2020.03.009
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., Cowen, P. J., & Harmer, C. J. (2025). An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders. Nature Mental Health, 3(3), 354–373. https://doi.org/10.1038/s44220-025-00390-x
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022). Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. International Journal of Molecular Sciences, 23(17), 9583. https://doi.org/10.3390/ijms23179583
Douton, J. E., Horvath, N., Mills-Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022). Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats. Addiction Biology, 27(2), e13117. https://doi.org/10.1111/adb.13117
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Drucker, D. J. (2024). Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care, 47(11), 1873–1888. https://doi.org/10.2337/dci24-0003
Eren-Yazicioglu, C. Y., Yigit, A., Dogruoz, R. E., & Yapici-Eser, H. (2020). Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol. Frontiers in Behavioral Neuroscience, 14, 614884. https://doi.org/10.3389/fnbeh.2020.614884
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Bowers, J., Srnka, A., Gavrieli, A., Ko, B.-J., Liakou, C., Kanyuch, N., Tseleni-Balafouta, S., & Mantzoros, C. S. (2016). GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: A crossover, randomised, placebo-controlled trial. Diabetologia, 59(5), 954–965. https://doi.org/10.1007/s00125-016-3874-y
Freet, C. S., Shuler, K., Kawasaki, S., Weintraub, E., Greenblatt, A., Kladney, M., Nunes, E., Foster, K. L., Kong, L., Raja-Khan, N., Cleveland, H. H., Grigson, P. S., Bunce, S. C., Brick, T. R., & Nyland, J. E. (2025). Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with oud: A randomized, double-blind, placebo-controlled clinical trial protocol. Addiction Science & Clinical Practice, 20, 89. https://doi.org/10.1186/s13722-025-00618-2
Gill, H., Badulescu, S., Shah, H., Brudner, R. M., Phan, L., Di Vincenzo, J. D., Tabassum, A., Thanarajah, S. E., Llach, C.-D., Rosenblat, J. D., McIntyre, R. S., & Mansur, R. B. (2026). Semaglutide and effort-based decision-making in major depressive disorder: A randomized clinical trial. JAMA Psychiatry, e260594. https://doi.org/10.1001/jamapsychiatry.2026.0594
Grigson, P. S. (with Milton S. Hershey Medical Center, New York University, University of Maryland, & National Institute on Drug Abuse (NIDA). (2025). GLP-1R agonist treatment for opioid use disorder (clinical trial registration no. NCT06548490). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06548490
Hendershot, C. S., Bremmer, M. P., Paladino, M. B., Kostantinis, G., Gilmore, T. A., Sullivan, N. R., Tow, A. C., Dermody, S. S., Prince, M. A., Jordan, R., McKee, S. A., Fletcher, P. J., Claus, E. D., & Klein, K. R. (2025). Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry, 82(4), 395–405. https://doi.org/10.1001/jamapsychiatry.2024.4789
Johns Hopkins University (with Eli Lilly and Company). (2025). Efficacy and safety of tirzepatide versus placebo or lisdexamfetamine dimesylate for binge-eating disorder: A randomized clinical trial (clinical trial registration no. NCT06847399). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06847399
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E.-S., & Williams, K. W. (2022). Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics. British Journal of Pharmacology, 179(4), 600–624. https://doi.org/10.1111/bph.15682
Kim, J. (2025). Glucagon-like peptide-1 receptor agonists and mental health: A narrative review of emerging benefits and risks. Journal of Yeungnam Medical Science, 42, 61. https://doi.org/10.12701/jyms.2025.42.61
Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., Fisher, P. M., Gillum, M. P., Jørgensen, N. R., Bergmann, M. L., Enghusen Poulsen, H., Becker, U., Holst, J. J., Benveniste, H., Volkow, N. D., … Fink-Jensen, A. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight, 7(19), e159863. https://doi.org/10.1172/jci.insight.159863
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022). The role of glucagon‐like peptide 1 (glp‐1) in addictive disorders. British Journal of Pharmacology, 179(4), 625–641. https://doi.org/10.1111/bph.15677
Knudsen, L. B., & Lau, J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155
Lähteenvuo, M., Tiihonen, J., Solismaa, A., Tanskanen, A., Mittendorfer-Rutz, E., & Taipale, H. (2025). Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry, 82(1), 94–98. https://doi.org/10.1001/jamapsychiatry.2024.3599
Leggio, L., Hendershot, C. S., Farokhnia, M., Fink-Jensen, A., Klausen, M. K., Schacht, J. P., & Simmons, W. K. (2023). GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nature Medicine, 29(12), 2993–2995. https://doi.org/10.1038/s41591-023-02634-8
Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Vukajlovic, T., Bologna, K., Steinmetz, M., Bathelt, C., Sailer, C. O., Vogt, D. R., Hemkens, L. G., Speich, B., Urwyler, S. A., Kühne, J., Baur, F., Lutz, L. N., Erlanger, T. E., Christ-Crain, M., & Winzeler, B. (2023). Effect of dulaglutide in promoting abstinence during smoking cessation: A single-centre, randomized, double-blind, placebo-controlled, parallel group trial. eClinicalMedicine, 57, 101865. https://doi.org/10.1016/j.eclinm.2023.101865
Lüthi, H., Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Vukajlovic, T., Bologna, K., Steinmetz, M., Bathelt, C., Sailer, C. O., Laager, M., Vogt, D. R., Hemkens, L. G., Speich, B., Urwyler, S. A., Kühne, J., Baur, F., Lutz, L. N., Erlanger, T. E., … Winzeler, B. (2024). Effect of dulaglutide in promoting abstinence during smoking cessation: 12-Month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine, 68, 102429. https://doi.org/10.1016/j.eclinm.2024.102429
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 | European Medicines Agency (EMA). (2024, April 12). https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024
Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Patil, S., Jha, N., & Jha, M. K. (2026). Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of clinicaltrials.gov. Addictive Behaviors Reports, 23, 100671. https://doi.org/10.1016/j.abrep.2026.100671
Paul, E. R., Östman, L., Heilig, M., Mayberg, H. S., & Hamilton, J. P. (2023). Towards a multilevel model of major depression: Genes, immuno-metabolic function, and cortico-striatal signaling. Translational Psychiatry, 13(1), 171. https://doi.org/10.1038/s41398-023-02466-7
Perez-Cheron, M. (2018). Remission of bulimia nervosa observed during administration of liraglutide and metformin: A case report. AACE Clinical Case Reports, 4(3), 199–202. https://doi.org/10.4158/EP161667.CR
Piątkowska-Chmiel, I., Wicha-Komsta, K., Pawłowski, K., Syrytczyk, A., Kocki, T., Dudka, J., & Herbet, M. (2025). Beyond diabetes: Semaglutide’s role in modulating mood disorders through neuroinflammation pathways. Cellular and Molecular Neurobiology, 45, 22. https://doi.org/10.1007/s10571-025-01534-4
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., Ismail, K., & Pillinger, T. (2025). Glucagon-like peptide 1 receptor agonists and mental health: A systematic review and meta-analysis. JAMA Psychiatry, 82(7), 643–653. https://doi.org/10.1001/jamapsychiatry.2025.0679
Radkhah, H., Rahimipour Anaraki, S., Parhizkar Roudsari, P., Arabzadeh Bahri, R., Zooravar, D., Asgarian, S., Hosseini Dolama, R., Alirezaei, A., & Khalooeifard, R. (2025). The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: A systematic review and meta-analysis. Eating and Weight Disorders: EWD, 30(1), 10. https://doi.org/10.1007/s40519-025-01720-9
Ren, G., Xue, P., Wu, B., Yang, F., & Wu, X. (2021). Intranasal treatment of lixisenatide attenuated emotional and olfactory symptoms via creb-mediated adult neurogenesis in mouse depression model. Aging, 13(3), 3898–3908. https://doi.org/10.18632/aging.202358
Research, C. for D. E. and. (2026). FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. FDA. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp
Richards, J., Bang, N., Ratliff, E. L., Paszkowiak, M. A., Khorgami, Z., Khalsa, S. S., & Simmons, W. K. (2023). Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. Obesity Pillars, 7, 100080. https://doi.org/10.1016/j.obpill.2023.100080
Richards, J. R., & Khalsa, S. S. (2024). Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. Obesity Reviews : An Official Journal of the International Association for the Study of Obesity, 25(5), e13709. https://doi.org/10.1111/obr.13709
Sa, B., Maristany, A., Subramaniam, A., Guillen, R., Buonocore, B., Smith, A., Oldak, S. E., & Padilla, V. (2026). Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence. Diabetes, Obesity & Metabolism, 28(1), 50–59. https://doi.org/10.1111/dom.70198
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L. (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. The Journal of Clinical Investigation, 124(10), 4473–4488. https://doi.org/10.1172/JCI75276
Sørensen, G., Reddy, I. A., Weikop, P., Graham, D. L., Stanwood, G. D., Wortwein, G., Galli, A., & Fink-Jensen, A. (2015). The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiology & Behavior, 149, 262–268. https://doi.org/10.1016/j.physbeh.2015.06.013
Suzuki, J. (with Brigham and Women's Hospital). (2025). Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trial (clinical trial registration no. NCT06639464). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT06639464
Tobaiqy, M., & Elkout, H. (2024). Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: A pharmacovigilance analysis of individual case safety reports submitted to the eudravigilance database. International Journal of Clinical Pharmacy, 46(2), 488–495. https://doi.org/10.1007/s11096-023-01694-7
University of North Carolina, Chapel Hill (with National Institute on Drug Abuse (NIDA)). (2025). Effects of semaglutide on nicotine intake and smoking lapse (clinical trial registration no. NCT05530577). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT05530577
Vinberg, M. (with Nordsjaellands Hospital). (2026). Is the GLP-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity (clinical trial registration no. NCT07136714). clinicaltrials.gov. https://clinicaltrials.gov/study/NCT07136714
Weina, H., Yuhu, N., Christian, H., Birong, L., Feiyu, S., & Le, W. (2018). Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Research, 1694, 55–62. https://doi.org/10.1016/j.brainres.2018.04.031
West, J., Li, M., Wong, S., Le, G. H., Teopiz, K. M., Valentino, K., Dri, C. E., & McIntyre, R. S. (2025). Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: A narrative review. Neurology and Therapy, 14(4), 1157–1166. https://doi.org/10.1007/s40120-025-00724-y
Xie, Y., Choi, T., & Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Medicine, 31(3), 951–962. https://doi.org/10.1038/s41591-024-03412-w
Yammine, L., Green, C. E., Kosten, T. R., de Dios, C., Suchting, R., Lane, S. D., Verrico, C. D., & Schmitz, J. M. (2021). Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: A pilot randomized controlled trial. Nicotine & Tobacco Research, 23(10), 1682–1690. https://doi.org/10.1093/ntr/ntab066
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Karolina Klusek, Michał Batory, Jakub Jakubowski, Karol Kraska, Nadzieja Krasucka, Aleksandra Zynkowska, Aleksandra Magdalena Skrzyniarz, Maria Kiełbus, Julia Oziębło, Magdalena Kijowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
